HighTower Advisors’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15,335
| Closed | -$136K | – | 3906 |
|
|
2025
Q1 | $136K | Buy |
15,335
+858
| +6% | +$10.3K | ﹤0.01% | 3294 |
|
|
2024
Q4 | $198K | Sell |
14,477
-3,550
| -20% | -$65.5K | ﹤0.01% | 3203 |
|
|
2024
Q3 | $493K | Sell |
18,027
-230
| -1% | -$6.23K | ﹤0.01% | 2407 |
|
|
2024
Q2 | $444K | Buy |
18,257
+3,328
| +22% | +$73K | ﹤0.01% | 2413 |
|
|
2024
Q1 | $316K | Sell |
14,929
-659
| -4% | -$14.2K | ﹤0.01% | 2642 |
|
|
2023
Q4 | $295K | Buy |
15,588
+176
| +1% | +$3.04K | ﹤0.01% | 2714 |
|
|
2023
Q3 | $252K | Buy |
15,412
+363
| +2% | +$6.91K | ﹤0.01% | 2738 |
|
|
2023
Q2 | $347K | Buy |
15,049
+362
| +2% | +$7.9K | ﹤0.01% | 2459 |
|
|
2023
Q1 | $340K | Sell |
14,687
-8,615
| -37% | -$175K | ﹤0.01% | 2374 |
|
|
2022
Q4 | $347K | Sell |
23,302
-1,203
| -5% | -$22.4K | ﹤0.01% | 2368 |
|
|
2022
Q3 | $470K | Sell |
24,505
-208
| -0.8% | -$4.77K | ﹤0.01% | 2066 |
|
|
2022
Q2 | $452K | Sell |
24,713
-266
| -1% | -$5.52K | ﹤0.01% | 2111 |
|
|
2022
Q1 | $630K | Sell |
24,979
-285
| -1% | -$7.29K | ﹤0.01% | 2025 |
|
|
2021
Q4 | $700K | Buy |
25,264
+433
| +2% | +$12.5K | ﹤0.01% | 1951 |
|
|
2021
Q3 | $799K | Buy |
24,831
+157
| +0.6% | +$5.21K | ﹤0.01% | 1783 |
|
|
2021
Q2 | $755K | Sell |
24,674
-2,402
| -9% | -$69.4K | ﹤0.01% | 1805 |
|
|
2021
Q1 | $822K | Buy |
27,076
+310
| +1% | +$8.8K | ﹤0.01% | 1695 |
|
|
2020
Q4 | $528K | Buy |
26,766
+1,160
| +5% | +$18.7K | ﹤0.01% | 1621 |
|
|
2020
Q3 | $331K | Sell |
25,606
-51
| -0.2% | -$645 | ﹤0.01% | 1775 |
|
|
2020
Q2 | $286K | Buy |
25,657
+4,497
| +21% | +$63.9K | ﹤0.01% | 1772 |
|
|
2020
Q1 | $304K | Buy |
21,160
+8,711
| +70% | +$184K | ﹤0.01% | 1562 |
|
|
2019
Q4 | $339K | Buy |
+12,449
| New | +$342K | ﹤0.01% | 1640 |
|
|
2018
Q4 | – | Sell |
-29,696
| Closed | -$1.36M | – | 2309 |
|
|
2018
Q3 | $1.36M | Buy |
+29,696
| New | +$1.32M | 0.01% | 995 |
|
|
2015
Q1 | – | Sell |
-16,223
| Closed | -$553K | – | 1667 |
|
|
2014
Q4 | $553K | Sell |
16,223
-38,509
| -70% | -$1.37M | 0.01% | 1014 |
|
|
2014
Q3 | $2.1M | Buy |
54,732
+7,533
| +16% | +$281K | 0.04% | 540 |
|
|
2014
Q2 | $1.84M | Buy |
47,199
+25,373
| +116% | +$944K | 0.03% | 588 |
|
|
2014
Q1 | $767K | Buy |
+21,826
| New | +$676K | 0.02% | 829 |
|
|
2013
Q4 | – | Sell |
-39,373
| Closed | -$929K | – | 1591 |
|
|
2013
Q3 | $929K | Buy |
39,373
+9,496
| +32% | +$270K | 0.02% | 646 |
|
|
2013
Q2 | $935K | Buy |
+29,877
| New | +$866K | 0.03% | 621 |
|
Other funds holding MYGN
GCM
HighTower Advisors's MYGN Position: Q2 2025 in Review
HighTower Advisors sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 15,335 shares — an estimated $136K sold.
HighTower Advisors first reported a position in MYGN in Q2 2013 and held it in 29 quarters. The position peaked at $2.1M in Q3 2014. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.
- HighTower Advisors reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
- HighTower Advisors sold 15,335 Myriad Genetics shares in Q2 2025, an estimated $136K.
- HighTower Advisors first reported a position in Myriad Genetics in Q2 2013 and held it in 29 quarters.
- HighTower Advisors's Myriad Genetics position peaked at $2.1M in Q3 2014.
- 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.
Based on HighTower Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.